680 A phase 1b open-label, single-arm dose expansion study of IK-175, an oral AHR inhibitor, in combination with nivolumab in patients with primary PD-1 inhibitor resistant advanced head and neck cancer
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.